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Applications of micro total analysis systems (μTAS) span basic-science research, clinical
medicine, and field work. Assay devices designed for these applications offer improvements
to existing methods or provide fundamentally new strategies. Both mature methods and
novel techniques have benefited from the increased throughput, integration and
miniaturization afforded by μTAS. Traditional assays such Western blots and binding assays
are recapitulated in a μTAS format but with reduced reagent usage, decreased performance
times and added capabilities. An increasingly vibrant area is the performance of drug
screening and toxicology assays on-chip, enabling the efficient screening of very large
numbers of molecules. Similarly, recent μTAS reactors demonstrate greater chemical
synthetic yields and novel product synthesis compared to macro-systems, often as a result of
accurate control over reaction conditions including precision reagent dispensing. These
exciting systems are now enabling on-site production of short-lived radioactive compounds
for medical applications. The greatest impact of μTAS may very well be the ability to
perform massively parallel laboratory experiments, for example, the use millions of reaction
vessels or the analysis of hundreds of thousands of single cells. Another strength of μTAS
lies in the creation of multicellular communities, for example, the combination of many cell
types into an interacting system to explore intercellular communication. Devices with
multiple layers of co-cultured tissues benefit from precise placement of molecules, such as
extracellular matrices or growth factors, in both space and time. Similarly, the complexity
and variety of organ-on-chip and organism-on-chip technologies continues to escalate
rapidly. Impressively, the types of organisms cultured on-chip now range from the simplest
bacteria to complex animals such as fish.
Automation, reliability, and integration must all increase as a device moves from the
specialist environment of a lab to usage by non-expert personnel in the outside world, for
example, at a clinical point-of-care or in environmental monitoring. Key innovations in
recent months result in devices that operate with minimal external equipment, error-free
operation, and unambiguous readouts, all critical for operation by untrained personnel.
Lightweight, portable devices are increasingly used to identify chemical and biological
toxins in water, air and soil with applications in public health, defense, and homeland
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security. Perhaps most exciting is the development of μTAS with sufficient robustness for
operation in challenging environments, such as the ocean and outer space. A central
component of these systems is the ability to withstand the unexpected. These systems push
the boundaries of current integration principles and spur rapid growth of new design
philosophies.
This review focuses on advances in the area of μTAS or “lab-on-a-chip” systems over the
time span of May 2011 through September 2012 with a focus on applications in basic
research, clinical medicine and field usage. A range of journals with 2011 impact factors
from 2.0 to 36.3 were screened to cover publications with highly specialized content as well
as those directed at multidisciplinary audiences. These publications included discipline-
specific journals such as Analytical Chemistry and Lab on a Chip as well as general
scientific publications, e.g. Science and Nature. To identify material beyond the individually
examined journals, extensive key word searches in databases such as PubMed, SciFinder,
and Web of Science were performed. Recent reviews in the area of μTAS were also
examined for appropriate references. Care was taken to identify impactful and exciting work
from across the globe. Well over a thousand papers in the three target areas were identified
and discussed. Due to space limitations, we were unable to include all papers but instead
incorporated those most fitting into the review scheme and those reporting innovations in
basic microdevice technology as well as in applications to biological, physical and
engineering sciences. We apologize in advance for omitted papers and welcome feedback
regarding any oversights on our part.
FUNDAMENTALS
This initial section focuses on the fundamental innovations in μTAS that underlie the
development of new devices and assays for the research setting, clinical lab and field
environment. Common goals for these innovations included improving device reliability and
repeatability as well as increasing device functionality by incorporating technologies not
commonly paired with μTAS. Many of these fundamental advances have led to miniaturized
replicas of macroscopic, industrial phenomena such as oil recovery, uranium fate, and
carbon dioxide solubility. Other applications included unique assays for the biological
sciences. These studies in the physical and biological sciences were often impossible to
perform with prior-art technologies and thus even the simplest applications revealed novel
phenomena and insights.
Microtechnology Advances
A broad range of improvements and innovations in microtechnology have been reported in
the areas of electronics, machinery, and fluidics. Here we focus on three aspects that are
closely related to μTAS-based applications: design advances, device fabrication, and surface
modification. Many recent advances have tackled universal challenges present in virtually
all μTAS, e.g. gaseous obstructions or surface fouling. Other developments embraced the
“green” movement to produce degradable systems to replace more commonly used long-
lived plastics/polymers.
Design—Using existing materials and established fabrication methods, novel microfluidic
designs can improve the ease-of-use of μTAS. For example, “reagent integrators,” filled
with dried reagents, were merged into a larger pair of sample-containing channels for
controlled reconstitution of the pre-deposited reagents.1 Other designs addressed unwanted
air bubbles that negatively affected device operation and experimental outcomes.
Phaseguides, which gradually advanced the liquid–air interface using meniscus pinning,
effectively eliminated trapped air bubbles in complex microfluidic geometries such as
corners and dead angles.2 To remove bubbles from a flow stream, a membrane-based
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debubbler was incorporated into microfluidic devices.3 Air bubbles were forced to discharge
through the porous membrane to the ambient environment while liquid flow continued
through the debubbler. These developments represent significant advances in eliminating a
phenomenon that has long plagued microchannels and compartments, i.e. undesired gas
accumulation due to failure to fully wet a device, insufficient degassing of fluids, or
electrolytic gas generation.
Fabrication—μTAS fabrication has matured, affording microstructure generation from a
wide range of materials (e.g. glass, silicon, elastomers, plastics, thermosets, paper) and using
an equally broad set of microfabrication methods (e.g. photolithography, soft lithography,
injection molding, hot embossing, laser micromachining). Recent innovations in fabrication
explored unconventional materials and fabrication strategies. Corn protein (zein) was
processed by soft lithography and bonded to both a glass slide and another zein film by
ethanol vapor deposition to form green microfluidic devices.4 An origami (paper folding)
method was developed to fabricate three-dimensional (3D) paper devices from single sheets
of flat paper in a single photolithographic step.5 Curved microfluidic networks were built
from the self-assembly of differentially photo-crosslinked SU-8 films, which spontaneously
and reversibly curled on film de-solvation and re-solvation (Figure 1a).6 Development of
these unconventional materials and fabrication methods has expanded the portfolio for
μTAS fabrication by offering the development of simple, low-cost, or biodegradable
devices.
Surface Modification—Recent innovations explored new surface modification methods
for specific μTAS applications. Perhaps the most common desired outcome for surface
alteration is a reduction in biomolecule adsorption, a challenging goal yet to be fully
addressed. To eliminate uncontrolled nonspecific bioadhesion on polydimethylsiloxane
(PDMS) surfaces, biomimetic glycocalyx-like nanofilms were synthesized using the
hydrosilylation click reaction and a methylated polysaccharide derivative (methylcellulose).7
This long-lasting, anti-adhesive coating may facilitate the use of PDMS in implanted
biomedical devices. Fabrication of superhydrophobic PDMS microchannels from a PDMS-
polytetrafluoroethylene (PTFE) composite was followed by isotropic etching of PDMS to
excavate PTFE particles; these surfaces reduced drag and viscous forces in microfluidic
applications.8
Integration with Other Technologies
μTAS have evolved from their primitive backbone platforms into highly advanced systems
by incorporating technologies from other physical science fields, including optics, acoustics,
electricity and magnetism, and mechanics. This integration benefits key functions in μTAS
and can lead to interesting biomimetic devices, such as camouflaged robots. Microfluidics
also enables new applications in other research areas by providing unique capabilities. The
interface between microfluidics and other fields establishes new research areas, such as
microfluidic electronics, which applies microfabrication strategies to produce flexible
electronic devices.
Optics—Optical readout (including colorimetry, absorbance, scattering, fluorescence and
luminescence) is the predominant detection method in μTAS, driving efforts to merge
microfluidics with photonic elements. A multiple internal reflection photonic lab-on-a-chip
for cell analysis integrated biconvex microlenses, self-alignment microchannels and air
mirrors.9 Another compact device monolithically integrated a gallium nitride blue light
emitting diode (LED) on a silicon substrate which served as a light source for the
fluorescence analysis system.10 The integration of these micro-optical elements on-chip can
reduce cost and enhance portability.
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Integration of microfluidics and optical components has also yielded unique control of
particles, fluids, and light. For example, optical forces can be used to precisely manipulate
particles and cells. Recently, a chip composed of silicon microring resonators integrated
with waveguides trapped particles and transferred them between rings.11 Optics can also
dynamically control and manipulate fluid flow. Reconfigurable flow pathways and
morphable channel structures (valves and traps) were created in seconds by illuminating an
optical pattern over a photothermal absorbing substrate and thermorheological solution.12
Optofluidic designs use fluidics to control light paths for displays, tunable apertures and
lenses, attenuators, switches, and lasers. Multilayer soft lithography produced optofluidic
microlenses with tunable focal length and zooming power.13 This system has potential
applications in portable microscopic imaging, bio-sensing, and laser configuration. A novel
nanoliter-sized microfluidic laser combined microdroplets and a capillary-based optofluidic
ring resonator.14 Tuning or switching of the lasing wavelength was achieved by merging
two different dye droplets in the microfluidic channel. These advances in optofluidics have
increased the flexibility of light-based sample manipulation and detection in chip-based
platforms.
Acoustics—Acoustic waves in μTAS have been applied to cell and particle manipulation,
fluid mixing and pumping. A pair of opposing surface acoustic waves induced rotation in a
fluid droplet at rates up to 2250 rpm.15 This microfluidic “motor” provided a unique,
miniaturized method for driving fast rotary motion that could easily be incorporated into
microfluidics for a truly portable lab-on-a-chip device. Similarly, rotation of a 10-mm disc
was driven by surface acoustic waves in a miniaturized centrifugal microfluidic platform
with no mechanically moving parts.16 For particle manipulation, interdigital transducers
controlled a standing surface acoustic wave field in real-time, producing acoustic tweezers
that manipulated single microparticles, cells, and organisms (Figure 1b).17 Use of acoustic
phenomena to control fluidic operations has tremendous potential since sounds waves
readily traverse devices without requiring specialized entry points or mechanical
components with complex moving parts.
Electricity and Magnetism—Electrical or magnetic control and detection have long been
paired with microdevices due to the ease of integrating electrodes or external magnets. In
particular, electrokinetic processes contribute diverse functionalities to μTAS such as fluid
transport, sample handling, and separation. Electric readout (e.g. impedance, conductivity,
and capacitance) is also a sensitive and versatile detection method in μTAS. For example, a
droplet sensor recorded blood pressure by measuring the surface capacitance at the
electrode–electrolyte interface.18 Other advances in electrowetting, such as unique tools to
manipulate tiny volumes of liquids in digital microfluidics, are covered in the Droplet
Manipulation section. Magnetism has also found increasing applications in fluid pumping,19
trapping, cell sorting and detection,20 and on-chip NMR.21
Electronics are widely used in off-chip instruments and have recently been combined with
microfluidics in unique ways. For instance, on-chip integration of organic electronics, e.g.
ion bipolar membrane diodes, has been demonstrated for controlling delivery of hydroxide
ions into a receiving reservoir for pH control.22 Additionally, the combination of
microfluidics with electronics opens a new, very early stage research area called
microfluidic electronics. Microfluidic electronics aims to make or integrate electronic
devices using microfluidic technologies. In one device, room temperature metal alloys were
processed in PDMS microfluidic platforms to build integrated electronic devices, such as
large-area strain sensors.23 These microfluidics-based, elastic electronics have appealing
applications, for example, in clothing-based medical sensing systems.
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Mechanics—Mechanical units are integrated in μTAS in the forms of valves, actuators
and pumps to manipulate fluid flow or to enable precise detection of mechanical stimuli,
such as pressure. A monolithic PDMS chip with integrated pneumatic lens arrays generated
a 2D pressure map by detecting pressure changes from 2-15 psi based on changes in focal
length.24 Microthrusters generated continuously variable thrust force up to 1 mN for a
miniaturized propulsion system with potential applications in next-generation micro-/
nanosatellites.25 Microfluidic technologies also contributed to novel mechanical devices.
Sophisticated motions (undulation and crawling) of soft robots built exclusively from
elastomer were controlled by pneumatic actuation of a series of pneu-net channels.26 The
result was a unique class of locomotive robot without conventional mechanical joints,
bearings or a hard skeleton, in which simple types of actuation produced complex motion.
Biomimetics—In a later section (Research Laboratory), we discuss cell-based organ
mimics; however, microfluidic technology is also generating abiotic systems with
functionality inspired by biology. One recent device mimicked fluid transport in plants,
replicating the osmotic pumping effects used in plant vasculature.27 Magnetic artificial cilia
were fabricated from photoreactive copolymer precursors and magnetic nanoparticles by a
new photolithographic process. The cilia were integrated into a microchannel and operated
using a rotating permanent magnet.19 While these biomimetics contributed new components
to μTAS, other devices were built entirely by biomimetic design, for example, a 3D gas
exchange unit based on vascularized lung-tissue.28 The soft robots/machines discussed
above were inspired by invertebrate animals (e.g., squid, starfish, worms),26 and their further
development mimicked the color-changing abilities of animals such as cephalopods, which
can change their color, contrast, pattern, apparent shape, luminescence, and surface
temperature for camouflage and display (Figure 1c).29 Finally, two recent microfluidic
devices were used as tissue surrogates (phantoms) for calibration and validation of imaging
methods, one standing in for human tissue in diffusion-tensor magnetic resonance imaging
(MRI) measurements30 and the other for superficial vascular networks in biophotonic
techniques such as laser speckle imaging or Doppler optical coherence tomography.31
Novel Physical Science
Fundamental advances in microfluidic technology enable new experimental studies, which
may be inadequately executed by macroscopic instruments. In the physical sciences, μTAS
have contributed to studies of porous media, emulsions and gas dissolution. In a reservoir
engineering application, a traditional water-flooding experiment based on rock samples was
replaced by a microfluidic device for studies of oil recovery.32 The device included a
realistic pore network representative of reservoir rocks and allowed direct visualization of
complex fluid flows and displacement mechanisms at the pore-scale. To study bacterial
motility or growth in simulated subsurface environments, one device permitted microscopic
examination of mixing in porous media mediated by bacterial motion;33 another device
investigated the spatial controls exerted by biomass and iron phases on uranium fate and
transport for biogeochemical cycling.34 Droplet microfluidics contributed to studies of
emulsions and gas dissolution. The kinetic parameters governing demulsification were
determined from the observation of thousands of individual coalescence events on an
integrated microfluidic device.35 These results inform predictions of emulsion stability in
industrial applications. Similarly, measurements of gas solubility, dissolution rates, and
rheology have a broad range of industrial applications. Microfluidics provided fast gas-
liquid reactions so that solubility data for carbon dioxide could be acquired systematically,
rapidly and without the need for manual intervention.36 Another high-throughput
microfluidic device was developed to generate a series of microrheology samples as droplets
in an immiscible spacer fluid.37 The composition of the sample droplets was continuously
varied over a wide range, maximizing the number of rheological measurements while
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simultaneously minimizing sample preparation time and amount of material. This method
should therefore be particularly suited to the characterization of scarce or expensive
materials. We expect many other macroscopic experiments to be miniaturized, but
researchers should carefully consider possible limitations or inaccuracies caused by
miniaturization of macroscopic phenomena.
Novel Biological Science
μTAS also enable collection of new biological data, either through novel devices or
groundbreaking applications of commercial devices. Many applications take advantage of
the ability of microfluidics to offer precise spatial and temporal control of chemical
environments. For example, conventional methods to ascertain the IC50 of matrix
metalloproteinases risk experimental error due to relatively small sample sizes, exacerbated
by serial pipetting steps. Two recent devices addressed this limitation by using precise
microfluidic methods to concentrate or dilute samples.38,39 Other examples of enhanced
fluid handling in biological assays included high-resolution temporal characterization of cell
lysis,40 sub-second hydrogen–deuterium exchange proteomics experiments,41 and single-
molecule investigations of ATP hydrolysis42,43 and nitrite reductase kinetics.44 Some new
devices used microfluidics to dispense ultra-low volumes off-chip, allowing precise
application of reagents in cell culture environments (Figure 2a,b),45,46 for scanning
electrochemical microscopy experiments (Figure 2c),47 and even to a living organism in
flight.48 Novel biological materials and results were also obtained through microfluidic
manipulation of lipid bilayers to produce, fuse, and otherwise assay giant vesicles.49,50 In
addition to these novel device designs, other recent papers described novel biological results
obtained from previously published43,44,51 or commercially available52-57 μTAS. While
these studies did not describe fundamental advances in microtechnology, they demonstrated
the critical contributions μTAS can make to diverse fields of biological inquiry, including
enzymology,43 whole-genome sequencing,51 cancer biology,52,57 ion channel gating,53
immunology,54 signal transduction55 and virology.56
RESEARCH LABORATORY
Biochemical assays
Although some μTAS enable entirely new assays not performable by traditional methods,
other devices improve on more established assays. The following sections provide examples
of recent advances in the areas of drug screening and immunosensing.
Drug Screening—Microfluidic devices have enhanced drug screening by permitting
detailed yet high-throughput studies of drug dissolution, membrane permeability, cellular
toxicology, and therapeutic effectiveness. A recent device using post structures captured
microparticles for dissolution studies in high flow rates that mimic in vivo conditions.58 A
key advantage for μTAS in pharmaceutical applications is the potential to screen large
numbers of drug compounds and formulations in small volumes, varying concentrations, and
at low cost. For example, one system improved throughput by using droplets to screen large
drug libraries against an important clinical target, protein tyrosine phosphatase 1B.59 μTAS
technology has also been incorporated into drug toxicity studies using cells, tissues, organs,
and organisms (with the latter two formats described in subsequent sections). An integrated
microfluidic array plate performed gravity-driven cell capture, cell culture, and drug
perturbation studies using real-time optical analysis,60 whereas another all-in-one device
incorporated a colorimetric assay to evaluate cadmium toxicity in liver cells.61 Another
device for studying liver cytotoxicity coupled microfluidics with ESI-Q-TOF mass
spectrometry to simulate in vivo drug metabolism, performing rapid on-chip testing and
sample pre-treatment before off-chip mass spectrometric analysis.62 Additionally, a high-
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throughput device utilized gradient generators to study pair-wise combinations of drugs on
prostate cancer cells, providing information about sequential or simultaneous
chemotherapies on a single population of cells.63
Similar multiplexed microfluidic devices have been applied to drug screening against
infectious organisms, an important application as bacteria become increasingly resistant to a
wide range of antibiotics. A pair of integrated droplet-based microfluidic devices permitted
rapid drug screening by encapsulating bacteria and antibiotics into droplets followed by
subsequent spectrophotometric analysis of cell growth within each droplet.64 An alternative
device used droplets to evaluate the effect of indole signaling on the development of
antibiotic resistance in bacterial colonies.65 Multiplexed microfluidic devices have also been
used to rapidly screen the effects of antibiotics on heterogeneous bacterial colonies to
identify resistant colonies using as few as 100 bacteria66 and to demonstrate how asymmetry
in cell division can lead to differential antibiotic sensitivity.67 Other studies examined the
effects of antibiotic concentrations and combinations; for example, microsegmented flows
created a three-dimensional concentration space to study drug combination/dose response
effects on E. coli.68
Immunosensing and Binding Assays—Immunosensing protocols often suffer from
high reagent costs and lengthy incubation times, which limit their utility in clinical settings.
Novel μTAS address these issues by decreasing reagent use and analysis time. For example,
experimental conditions for immunofluorescence assays of lysosomal storage disorders were
optimized using pneumatic valves for parallel staining.69 A Western Blot-on-a-chip device
incorporated both gel electrophoresis (SDS-PAGE) and blotting steps on a single device,
providing faster sample analysis, lower reagents costs, and a ‘renaturation’ step to remove
SDS-PAGE reagents that could negatively impact affinity agent binding.70 Additionally, an
enzyme-linked immunosorbent assay (ELISA)-on-a-chip was developed with comparable
limits of detection (10 pg/mL) to traditional ELISA but greatly reduced antibody
consumption and assay time.71 For immunoassays in tissues, a vertical microfluidic probe
enabled staining of individual cores of tissue microarrays, diminishing antibody cross-
reactivity and increasing the range of staining conditions applied to a single tissue section.72
Another major thrust of immunosensing in μTAS is the development of devices capable of
rapid protein sensing with low detection limits. A recent device incorporated pH specific
membranes to pre-concentrate, separate, and quantify glycoproteins directly from biological
samples.73 Microfluidic devices employing magnetically-labeled cells also performed high-
throughput analyses with low limits of detection. Recent examples included a giant
magnetoresistive biosensor to evaluate protein-antibody binding74 and a micro-Hall detector
to measure immunomagnetically tagged cells in whole blood.20 Antibody-functionalized
microspheres provided another method to concentrate samples and improve detection limits.
Microfluidic immunoassays based on polymer and magnetic microparticles were used to
detect cytokines,75 cyanotoxins,76 and breast cancer biomarkers.77 In addition to low
detection limits, many devices also featured high levels of automation,78 rapid analysis
times (10-30 min),76,78 and adjustable dynamic ranges.77 Finally, the immunosensing
capabilities of μTAS have also contributed to studies of key molecules in cell signaling
pathways by probing for cell surface markers79 and molecular distributions of diffusible
molecules,80 or by studying binding kinetics using surface plasmon resonance (SPR).81
High Throughput—μTAS are often highly automated, and as a result, increase assay
speed. Additionally, micron-scale components expand the number of possible components
on a single chip, facilitating multiplexed analysis. High-throughput μTAS have particularly
benefited biological and biochemical assays. Automated proteomics assays in gel-based
microfluidic devices had a 5- to 15-fold improvement in speed for prostate specific antigen
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detection compared to conventional Western blotting and a two-fold improvement over
traditional capillary immunoblotting.82 Other systems provided rapid screening of millions
of analytes, such as genes for engineered proteins based on directed evolution83 and affinity
reagents for membrane-bound receptors on adherent cells.84 Microfluidic devices also
facilitated rapid inspection of particles and cells. For example, a label-free nanoparticle
analyzer with resistance-based detection determined the size and concentration of ~500,000
particles per second in blood-sample analysis,85 and a droplet-based system screened
300,000 hybridoma clones in less than a day.86 The small footprint of device components
also facilitated high-density multiplexing on individual devices, for instance, a 16-channel
device for chromatin immunoprecipitation.87 Advanced multiplexing has encompassed
much larger numbers of components. A microfluidic flow cytometer used 384 parallel flow
channels to investigate nuclear translocation events in models of disease states caused by
protein misfolding.88 Another device included >900 micromechanical valves, creating a
versatile device that could be controlled by software programming for a variety of
functions.89
Synthesis
Precise control over small volumes and mixing has driven the use of microsystems as
microreactors. Many of these systems have been used for the production of pharmaceuticals
and imaging agents, and some even incorporated analyses of synthesized products on the
same chip.
Microreactors—Chip-based systems have assembled a number of biomolecules, including
proteins and DNA. Cell-free protein production was achieved using an array of cellular-
scale porous containers housing transcription/translation reagents and a DNA template.
Amino acids and other necessary reagents flowed through the system, and synthesized
proteins were readily released from the porous vessels (Figure 3a),90 yielding twice the
protein per volume compared to conventional batch production. Synthesis followed by
subsequent analysis on a single device has also been demonstrated; for example,
measurement of pH, temperature, and attenuated total reflection Fourier-transform infrared
(ATR-FTIR) spectra for reaction characterization.91 In many cases, microfluidic reactors
also simplified chemical reaction steps. For example, the optical transparency and gas
permeability of a PDMS device allowed photosensitized oxygenation reactions to be
completed without gas presaturation, reducing reaction times from hours to minutes.92 A
simple flow-based device coupled aqueous and ionic liquid droplets, allowing a soluble
analyte to diffuse between droplets and catalyze a fluorescent reaction (Figure 3b),93 while a
more complex device utilized electrocoalescence to perform synthesis by droplet fusion
(Figure 3c).94 Another device even mimicked natural plant photosynthesis, performing
photoenzymatic synthesis using quantum dots and redox enzymes on-chip (Figure 3d).95
Numerous on-chip techniques have been devised to synthesize solids, including
microspheres, nanoparticles and fibers. These devices yielded stable, uniformly sized
particles, as in a recent synthesis of supramolecular microcapsules.96 Other on-chip
syntheses formed products not possible in bulk reactions, such as the self-assembly of block
copolymer micelles into kinetic cylinders, y-junctions, bilayers, and networks, while only
spheres can be produced in bulk reactions.97 Improvements in microfluidic devices, such as
the ability to withstand high pressures and temperatures, have permitted the use of
supercritical microfluidics, allowing the synthesis of materials with advanced optical
properties, such as ultraviolet (UV)-emitting zinc oxide (ZnO) nanocrystals.98 Some devices
used microfluidic handling to prepare nanoparticle-containing microparticles, for instance,
alginate microparticle barcodes doped with varying ratios of quantum dots.99 Not only can
these solids be synthesized on-chip, but some can also be arranged, combined, and
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immobilized. A polymethylmethacrylate (PMMA) device fabricated chitosan microparticles,
and then linked these particles together, controlling microparticle arrangement and chain
length.100 Other devices produced and deposited ZnO nanowires101 or metal-organic
frameworks102 on-chip. Novel devices have also formed continuous solids, such as fibers
and complex, elongated structures. A two-layer device designed to mimic a silkworm gland
controlled fiber properties of synthetic silk for characterization of sequence-structure
relationships,103 and two-photon continuous flow lithography was used to produce extended
3D structures such as helices in a PDMS microdevice (Figure 3e).104
Pharmaceuticals and Imaging Agents—Microreactor platforms have frequently been
applied to biomedical challenges, such as drug synthesis, packaging, and formulation. A
microfluidic spray dryer produced amorphous drug nanoparticles of narrow size distribution
from a drug-loaded spray,105 while a T-junction device controlled antisolvent precipitation
for size-tunable formation of drug nanoparticles.106 The synthesis of therapeutic delivery
devices is another active area of research. Recent microfluidic devices have packaged
therapeutic nucleic acid materials, plasmid DNA cores107 and siRNA108 in lipid bilayer
shells. Another system covalently linked drug molecules to delivery agents in an efficient
synthesis of heparin-folic acid-retinoic acid bioconjugates.109 Additionally, advances in the
synthesis of imaging agents were possible due to the use of droplet-based technology or on-
site synthesis of short half-life reagents. Flow focusing chips produced phase-change
perfluorocarbon droplets that act as acoustically activated contrast agents for MRI.110
Multiple devices also aided in the synthesis and labeling of fluorine-18 radiotracers for
positron emission topography (PET) scanning, including an electrowetting on-demand
device to synthesize fluorodeoxyglucose[18F]111 and a droplet generation device to
optimize labeling of anti-prostate stem cell antigen diabodies with an 18F-containing small
molecule.112 Microdevice-based synthesis of 18F-labeled molecules will enable a much
broader application of this radioisotope since the molecules are produced on-demand and
used prior to significant decay.
Digitization
As noted in the synthesis section, many μTAS take advantage of the precise volume control
found in microfluidic systems. The ability to manipulate fluids as micro- or picoliter scale
droplets, known as digitization, has opened the field to new and exciting applications.
Droplet Generation—Common droplet generation techniques use tapered microchannels
to produce droplets from a continuous flow stream; however, several recent devices have
used light sensitive reagents for droplet generation. UV light was used to solidify a hydrogel
encapsulating an active compound-containing oil core.113 The encapsulated molecules were
then released by simple hydration without the temperature stimulus commonly needed for
hydrogel release. Another droplet generation system used a photo-sensitive surfactant to
produce droplets. UV light released droplets from a continuous stream as a result of a
change in surface energy.114 Other devices improved control of droplet properties. For
example, a PMMA device utilized coaxial microfluidic channels to form gas-in-water-in-oil
or gas-in-oil-in-water double emulsions with a high degree of control over encapsulated
bubble size, number of encapsulated bubbles, and droplet size (Figure 4a).115
Droplet Manipulation—Just as droplet generation techniques have progressed, new
methods and applications for droplet manipulation have also been developed. An electrode
grid moved individual droplets across an array to reagents stored either directly on the
electrodes116 or on hydrogel disks.117 These devices were applied to dried blood spot
analysis (Figure 4b),116 cell culture and evaluation,118 and proteomics studies.117 Other
electrowetting systems enabled handling and crystallization of proteins for in situ matrix-
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assisted laser desorption/ionization mass spectrometry (MALDI-MS) analysis.119 A recent
improvement to electrode-based manipulation systems utilized a thin film transistor array to
replace conventional patterned electrodes, allowing the fabrication of larger arrays (64 × 64)
by eliminating individual electrode connections.120 Surface acoustic waves have been
utilized in combination with a series of Fabry-Perot resonators for interaction-free droplet
manipulation.121 In open devices, surfactant-containing droplets were self-propelled along
patterned thin films of sodium dodecyl sulfate in glycerol without the need for external
actuation (Figure 4c).122 Electrowetting techniques have even performed three-dimensional
droplet manipulation. Energy was stored by stretching droplets using electrowetting forces,
then released upon the removal of the forces, causing the droplets to ‘jump’ off a surface
(Figure 4d).123
Droplet Analysis—Precise manipulation of large numbers of droplets facilitates screening
over extended time periods. By storing a well-defined array of protein-containing aqueous
droplets, time-lapse analysis of nucleation processes, such as the formation of amyloid
bodies, was possible.124 The ability to perform this analysis will contribute to studies of
Alzheimer’s, Parkinson’s, and diabetes mellitus type 2, which all involve pathological
deposition of protein fibrils. In another system, oil-in-water droplets encapsulating cell
lysates with antibody-functionalized beads were stored and analyzed on-chip for
intracellular protein determinations.125 This system yielded faster results than conventional
immunoblotting while requiring fewer cells.
PCR
μTAS platforms offer a variety of unique advantages for nucleic acid assays based on
polymerase chain reaction (PCR). Massively parallel fabrication permits digital PCR in
large numbers of reaction vessels while integration of sample processing and miniaturization
benefit total assay performance by reducing sample and reagent consumption. Care must be
taken, however, in the design of μTAS platforms because many common materials used in
microfabrication, such as PMMA and SU-8 photoresist, have been shown to inhibit PCR
reactions.126
Digital PCR—Traditional quantitative PCR (qPCR) assays suffer from limited precision
and thus face challenges in quantifying absolute gene copy numbers. Digital PCR, which
amplifies individual molecules in discrete reaction volumes, eliminates this shortcoming.
While previous implementations of digital PCR in microfluidic reaction vessels achieved
densities as high as 6,000 cm−2, valve-less implementations achieved up to 440,000 vessels
per cm2 by filling the reagent loading channels with oil (Figure 4e).127 A robust
implementation of digital PCR in a SlipChip format yielded quantitative results even with
isothermal amplification at various temperatures.128 Another SlipChip multiplexed reverse-
transcriptase PCR (RT-PCR) reactions in a multi-volume format for high dynamic range
(from 1 to 1.2×105 copies) in a relatively small total number (880) of reaction vessels.129
The high dynamic range inherent in digital PCR has enabled the study of rare genomic
events. This feature was exploited in the quantitation of rare KRAS mutants against a large
background (1 in 200,000) of wild-type genes.130 With at least five commercial
implementations of microfluidic digital PCR available on the market, this technique has
become a μTAS success story.
Single-Cell PCR—Systems designed for digital PCR are optimized to isolate
approximately 1 gene copy per vessel from diluted reaction mixtures. The technologies
developed for digital PCR therefore translate readily to similar analyses on single cells. PCR
on single bacteria isolated from the termite hindgut identified viral marker genes to explore
phage-host interactions.131 A valve-based microfluidic platform was used to trap, lyse and
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perform RT-PCR on single mammalian cells for the quantitation of RNA expression in
single cells.132 In addition to valve-based systems, a droplet-based microchip performed
RT-PCR on canine kidney cells, creating the droplets, thermocycling and performing
fluorescence readout by microscopy on-chip.133 These devices offered high sensitivity, wide
dynamic ranges, and highly parallel designs, which allowed experiments to be conducted on
hundreds to thousands of individual cells at once, a feature critical to the broader relevance
of such devices.
Genotyping—From forensics to infectious diseases, rapid and accurate characterization of
genetic samples has a variety of valuable applications. The high surface area-to-volume ratio
of μTAS is particularly relevant in capture-based detection modalities, including giant
magnetoresistive materials, which provide direct electrical readout of binding of
biomolecules to tethered probes. Giant magnetoresistive sensors were recently used to
genotype the four variants of hepatitis B virus, data that may be of clinical relevance in
diagnosis and therapy.134 The ability of μTAS platforms to couple diverse functionalities
has been well-demonstrated in genotyping applications. An excellent example incorporated
continuous-flow PCR amplification, bioaffinity-based sample purification and
concentration, and detection by capillary electrophoresis for gender and ethnicity
determination of genetic samples.135 The combination of readily interpreted readout and
functional automation have also made μTAS devices an appealing platform for developing
world applications. A ligase detection reaction and conventional PCR amplification were
integrated into a single-chip solution for the genotyping of drug-resistant M.
tuberculosis.136The multiplexing advantages of the μTAS format allowed the integration of
three controls and six target genes for detection into a single readout. For the
characterization of complex and poorly understood systems, genome-wide screening is
necessary in order to enable rapid genotyping, particularly in clinical samples. Gene
expression profiles of non-small cell lung cancers were obtained using Fluidigm’s
BioMark™ microfluidic platform and were used in combination with DNA methylation data
to correctly differentiate between epithelial- and mesynchemal-derived cancers.57
Cell-Based Assays
Microfluidic devices have enabled many studies of biological processes including cell
migration, cell proliferation, cell-to-cell signaling, and single-cell analysis. Low sample
volumes, rapid incubation times, and more quantitative outputs have driven the development
of new and improved devices. Many exciting developments in cell-based technology are still
confined to the research laboratory but have the potential to enhance our understanding of
essential biological pathways.
Microfluidic Cell Culture—Microfluidic devices provide several advantages over
macroscale cell culture, such as lower reagent volumes, automation and controllable cell-cell
interactions. Recent advances improved cell culture efficiencies by automating control over
carbon dioxide and oxygen levels,137,138 temperature, and cell density over prolonged
periods in both closed channels139 and digital systems.118,140 Multichamber cell culture
devices recently demonstrated cell culture under low shear conditions141 or continuous
perfusion.142 A gravity-driven device, using the principle of equivalent electric circuits,
alternated the hydraulic resistance of channels to culture uniform 3D cell spheroids in < 24
h.143 Another device accurately evaluated cell layer integrity using transendothelial
electrical resistance to measure impedance, providing an automated method to measure
cellular confluency independent of visual inspection.144 Additionally, microfluidic devices
have been developed to quantify proteins secreted from cells cultured on-chip. A novel
quantitation method used mass spectrometric imaging to determine the distance secreted
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proteins travelled down a channel as a replacement for traditional, less quantitative MS peak
intensities.145
The ability to perform long-term cell culture under well-defined conditions while tracking
individual cells has enabled important studies of cell aging and microbial communities. For
example, a microfluidic device trapped 60 individual yeast cells while continually removing
daughter cells over a three-day period,146 while another employed fluid flow to selectively
release and track newly-budded daughter cells through several generations (Figure 5a).147
Cell aging and evolution of bacterial cells were also investigated by monitoring the
formation of daughter E. coli cells as they developed within a confined microchannel.148
Microscale microbial communities have also yielded important information about their
complex growth dynamics. Recent examples included a synthetic oscillator consisting of a
dynamic switch upstream of a cell trapping region that controlled activation signals for a
bacterial biological clock,149 algal cultures in discrete droplets that revealed heterogeneous
cell populations,150 and a simple microfluidic device that gave insight into the trade-off
between local competition and dispersal in a growing biofilm of Vibrio cholera.151
Microenvironment Control—A major advantage of on-chip cell-culture is the ability to
control the cellular environment on the microscale. Consequently, μTAS have provided
researchers with tools to investigate key biological processes, including cell migration and
chemotaxis, adhesion, and cell-to-cell crosstalk. One device took advantage of two
alternating inlet channels to elicit competing gradients, effectively trapping the slime mold
Dictyostelium discoideum due to constant readjustment of cell polarity.152 In another
device, epithelial cells “sensed” their way through a microfluidic maze following an
epidermal growth factor (EGF) gradient (Figure 5b).153 A recent device utilized
electrochemical impedance spectroscopy coupled with a traditional Boyden chamber to
more quantitatively evaluate hepatocellular carcinoma migration in response to different
extracellular matrix (ECM) proteins.154 Additionally, microfluidic control of the cellular
microenvironment has elucidated the roles of essential proteins in cell behaviors, such as
fibroblast chemotaxis155 and electrotaxis.156 Microfluidics also enabled studies of
chemotropism, directed growth in response to a chemical gradient, through precise spatial
and temporal control of pheromones to induce the mating response, or formation of
“shmoos,” of Saccaromyces cerevisiae.157 Changes in interstitial flow through the
extracellular matrix, common during inflammation, can also affect the morphology and
migration of cells; however, the ability to directly visualize this response has been limited. A
microfluidic system addressed this shortcoming and demonstrated that interstitial flow
strength caused a directional bias of melanoma cell migration and affected the percentage of
cells that became migratory.158
The cellular microenvironment often includes other cell types in addition to soluble factors
and ECM. Several devices integrated soluble gradients and endothelial monolayers for
transendothelial invasion studies. For example, adenoid cystic carcinoma cells migrated
through an endothelial cell monolayer to a chemokine-loaded ECM (Figure 5c),159 and
tumor intravasation was studied as a function of an external EGF gradient and endothelial
paracrine signaling.160 Novel devices also elucidated the role of proteins such as selectins on
neutrophil adhesion, a necessary step in inflammation.161 Cell migration is often the result
of cellular crosstalk. Recent devices were used to evaluate kidney cell migration toward
fibroblasts across a “wound” generated without mechanical tension on adjacent cells.162
Other μTAS have adjusted the microenvironment of the cell to study paracrine and
autocrine signaling. Two recent devices used microfluidic flow to reduce the concentrations
of secreted factors from mouse embryonic stem cells, providing valuable insight into
signaling dynamics and differentiation.163,164
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As μTAS cell culture continues to evolve, the designed devices more effectively recapitulate
in vivo microenvironments. Recent microfluidic technology has generated on-chip mimics
of angiogenesis, the cardiovascular system, and mechanical stimuli of organ systems. A
ground-breaking device induced capillary formation by culturing human umbilical vein
endothelial cells (HUVECs) on either side of a fibrin gel.165 Over time, HUVECs migrated
into the gel and ultimately formed leak-free, perfusable vessels (Figure 6a). Another
microfluidic vascular network demonstrated angiogenic remodeling, perivascular cell
crosstalk, and the interaction between blood components and the endothelium.166 Other
devices for angiogenesis studies examined leukocyte recruitment to new capillaries,167 the
effects of matrix metalloproteinases on capillary diameter and elongation rates,168 and the
effects of interstitial flow, a vascular endothelial growth factor gradient, and shear forces on
endothelial sprouting in a collagen matrix.169 Fabrication of degradable glass filaments
within endothelial cell cultures provided a better mimic of the vasculature network (Figure
6b).170 Other cardiovascular organ-on-a-chip systems focused on the electrical and
mechanical stimulation of heart cells. A cardiomyocyte culture on an elastomeric membrane
provided a system for monitoring applied stresses during cell contraction.171 A novel in
vitro platform modeled cardiac muscle on a multielectrode array-based biochip and
measured the electrical conductivity of laser-patterned stem cells bridging cardiomyocytes,
an important factor in successful stem cell grafting to treat ischemia or infarction.172
Mechanical and shear stresses were also applied to systems modeling the colon173 and lung
airways.174 While these systems have certainly advanced our understanding of cell
interactions and fates, researchers should apply the “organ-on-a-chip” label selectively. True
organ-on-chip systems must mimic organ microarchitecture (e.g. biophysical) and
microenvironment (e.g. biochemical, mechanical) and generate organ-level physiological
responses under external stimuli (e.g. toxins, bacteria, drugs etc.). Tumor cell lines should be
avoided since their aberrant biology poorly reflects normal tissue physiology. Instead,
primary cell lines and realistic co-cultures should be employed wherever possible.
Organism-on-a-Chip
While whole organism studies might seem like an odd application for microscale
technologies, μTAS devices have provided high-throughput and sensitive analysis of small
organisms, such as plants, protozoa, zebrafish and worms. For example, directional pollen
tube growth towards an unfertilized ovum in microfluidic channels provided controllable
analysis of the mechanisms of plant reproduction.175 In addition to templating growth,
microfluidics also aided in continuous monitoring of individual organisms over prolonged
time periods. For example, microfluidic flow trapped individual Tetrahymena thermophila, a
highly motile protozoan ciliate, for up to 40 hours.176 μTAS have also reduced analysis time
by trapping organisms in parallel microcompartments, as exemplified by the development of
8-well and 48-well chambers for the study of zebrafish177 and Caenorhabditis elegans,178
respectively. Additionally, microfluidic devices have been used to examine the
chemosensory crawling behavior of C. elegans, a difficult task for traditional technologies.
One apparatus elucidated the role of interneurons on head movement in response to calcium
stimuli,179 while another platform evaluated migratory turning dynamics in response to
liquid-borne stimulation of the olfactory system (Figure 6c).180 Drug screening on intact
model organisms has also been incorporated into microfluidic devices. Microfluidic
platforms evaluated the effects of anthelmintic drugs on two nematode species, C. elegans
and parasitic Oesophagotomum dentatum. These devices provided a variety of readouts,
including real-time observation of pre-, concurrent, and post-exposure locomotion,181
muscular force measurements based on cantilever deflection,182 and non-invasive
quantification of electrophysiological activity.183 The capabilities of μTAS systems to
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enable new biological assays and reproducibly screen high numbers of organisms will likely
result in increased employment of these devices as they mature.
Single Cells
Recent technologies designed for analyzing individual cells have revealed inherent cellular
heterogeneity. The biological importance of this heterogeneity has resulted in a plethora of
strategies for manipulating, sorting and analyzing individual cells from mixed populations.
Single-Cell Analysis—Because population-based studies do not yield an accurate picture
of cellular heterogeneity, microfluidic devices have been developed to isolate single cells
and analyze them in a high-throughput fashion. Recent techniques applied cell trapping and
mechanical methods to study intact cells or to analyze the intracellular contents of lysed,
single cells. Microchambers were used to trap up to 340 single-cell pairs while tracking
intercellular signaling.184 In another study, a multiplexed platform integrated cell culture
and stimulation with downstream analysis, including live cell fluorescent microscopy and
flow cytometry, to profile toll-like receptor 4 (TLR4) signaling in single lipopolysaccharide-
stimulated macrophages.185 Additionally, well-controlled fluid flow has transported single
cells through microchannels for density measurements.186 Another device measured the
deformability of red blood cells as they passed through a constriction and distinguished
healthy cells from those parasitized by Plasmodium falciparum based on stiffness.187 Other
devices use on-chip lysis for analysis of intracellular contents.125,132,188 One device
captured and isolated 100 cells in reversibly sealed microchambers for incubation, washing,
labeling, and eventual lysis.189 This platform was used to monitor single-cell NADPH/
NADH dynamics and the toxic impact of the alkaloid camptothecin.
Advanced microfluidic systems are using quantitative single-cell measurements to reveal
biologically important heterogeneity in cell populations. More than ten types of secreted
proteins from single immune effector cells were measured using 1040 3-nL microchambers,
demonstrating functional heterogeneity in phenotypically similar cytotoxic T-cells.190
Digital microfluidic devices have proven especially useful in single-cell analysis due their
programmability and inherent compartmentalization of small volumes. One multipurpose
platform consisting of 95 separate storage chambers sorted, isolated, and processed single
cells by alternating droplet immobilization by flow-controlled wetting.191 This chip was
used to genotype single bacteria from multiple environments ranging from deep-sea
sediments to the human oral cavity. Another digital device incorporated a rolling-circle-
enhanced enzyme activity detection (REEAD) assay to detect rare, aberrant single cells from
a wild-type population.192 Through the continued advancement of μTAS technology, single-
cell assays will be more readily available to researchers, reducing high experimental costs
and long assay times and revealing results obscured by ensemble measurements of
heterogeneous cell populations.
Manipulating and Sorting Individual Cells—Precise control of small volumes makes
microfluidic technologies ideal for manipulating individual cells for fusion, transfection,
staining, or sorting. Cell pairing is a critical step in fusing genetically dissimilar cell types to
create hybridomas. Recent microscale systems employed dielectrophoresis to selectively
mate pairs of cells for subsequent fusion.193 In addition to cell pairing, multiple strategies
have been described for sorting, capturing, and collecting rare cells. While traditional size-
and deformability-based separations have been plagued by clogging, a novel device
overcame these issues by incorporating a series of microstructure funnels to flow cells
irreversibly, even under oscillatory flow conditions.194 Another strategy employed
dielectrophoresis to isolate C2C12 myoblasts from differentiating myotubes.195 A
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centrifuge-on-a-chip harnessed fluid vortices to combine cell sorting with subsequent
sample processing, including concentration, staining, and wash steps on-chip.196
Exceptionally rare cell types, such as circulating tumor cells (CTCs), require further
refinement of cell sorting methods. Because of mounting epidemiological and molecular
evidence that CTC numbers predict cancer metastasis and patient outcome, CTC enrichment
and recovery is a growing area of research. While macroscale immunomagnetic collection of
CTCs via anti-epithelial cell adhesion molecule (EpCAM) labeling remains the gold
standard, several competing microscale platforms have been developed. These platforms
have extended the capabilities of macroscale collection to improve enrichment rates and
recover viable CTCs. For example, magnetically-labeled CTCs were detected by a micro-
Hall detector with parallel sensor arrays at higher sensitivity than currently possible with
clinical standards.20 A robust, single-channel device for immunomagnetic collection of
CTCs by anti-EpCAM binding captured 86-90% of cancer cells spiked into whole blood at
flow rates of 10 mL/h.197 This device functioned on the same principle as macro-scale
implementations such as CellSearch™ by Veridex, but reduced reagent consumption by
25% and improved capture efficiency. Moving away from immunomagnetic capture,
“virtual aliquots” were produced as plugs of whole blood containing a target cell were
identified by fluorescence and separated from continuous flow with high recovery rates
(93%).198 The limitations of anti-EpCAM capture have also been demonstrated; a
microfluidic device composed of functionalized micropillars increased capture rates over
CellSearch™ up to 400-fold using an antibody to a prostate-specific membrane antigen in
samples from 25 prostate cancer patients in a clinical setting.199 Most immunomagnetic and
surface capture methods irreversibly bind tumor cells, preventing their recovery and
reducing cell viability. By anchoring capture antibodies to an alginate biopolymer,
researchers enabled rapid and efficient release of captured CTCs by incubation with alginate
lysase.200 To move CTC devices from the research laboratory to the clinic, future devices
should offer efficient capture, on-demand release, and sensitive analysis of these rare cells.
CLINIC
Successful devices for clinical applications must perform as well or better than current
assays, adhere to stringent production and operation requirements, and have a medically-
useful dynamic range with high sensitivity and specificity. When these criteria are met,
microfluidic technology offers several advantages over conventional assays. Parallelization,
automation, and multiplexing reduce the total read time for time-sensitive clinical assays.
Reduced reagent consumption and automated sample preparation minimize assay costs and
bring quality clinical assays to resource-poor settings. Recent research efforts have focused
on platforms with one or more of the following functions: handling of soluble analytes,
analysis of intact or lysed cells, and integration of assays for point-of-care devices.
Soluble Analytes—Microfluidic platforms have advanced analysis of soluble analytes in
human fluid samples, including blood, urine, saliva, sputum, and tears. In particular,
automated pre-processing of clinical samples has enabled efficient analyses. For example,
recent methods have separated analytes from whole human blood using microfiltration,201
cationic isotachophoresis,202 or paper-based203 flow prior to subsequent analysis. Fluid
control was the central focus of a device used to count CD4+ lymphocytes for HIV staging
from a fingerstick.204 The device featured an antibody-impregnated hydrogel layer that
controlled antibody release via swelling once blood was applied. Two devices integrated
sample separation with on-chip analysis of cardiac biomarkers.203,205 Microdevices have
also quantified other important serum components, including sugar moiety alterations on
bloodstream proteins (useful in stratifying patients with esophageal cancer)206 and cobalt
ions (contained in the vitamin B12 complex).207
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Because of their ability to filter and separate analytes, paper microfluidic devices are well-
suited to separations of human-derived fluids. Filtration can be achieved either
horizontally203,208 or vertically,209,210 and applied to blood,203,209 urine,208 or sputum.210
For example, one device added a second stage to a conventional lateral flow assay to form a
“two1dimensional paper network” that enhanced the sensitivity of an immunoassay-based
pregnancy test.208 While these devices were composed of paper, a more traditionally-
fabricated digital device reconstituted and manipulated paper-based samples for dried blood
spot analysis using off-chip MS.116 Devices like these integrate multiple sample preparation
steps on-chip with high precision and control.
While most reports on sample preparation focused on blood, other fluid samples are
routinely analyzed in clinical labs. One group used microchip electrophoresis to separate and
quantify three markers of kidney stone formation in urine in a single 10-min run.211 While
blood and urine sample volumes are generally milliliter-scale, microfluidic platforms also
offer the ability to assay soluble analytes in lower-volume samples such as saliva, sputum,
and tears. A simulated sputum sample was analyzed using a foldable paper-based device,210
and one group used on-chip alkaline electrophoresis to analyze protein biomarkers in tear
samples from autoimmune patients in just 5 s.212 These samples were microliter-scale,
demonstrating the utility of microfluidic platforms for low-volume samples that could not be
accurately assessed by conventional methods.
Cellular Analysis—Sensitive, specific cell-based assays on-chip have been applied to
intact or lysed human cells and to detection of pathogenic microorganisms in clinical
samples. In some devices, the readout was based on the flow characteristics of cells in the
sample. One study, for example, used microfluidic flow to study the deformability of cells
obtained from chest wall fluid to screen for cancer and achieved sensitivity and specificity
of 91% and 86%, respectively (Figure 7a).213 In another example, researchers decreased
sample oxygen content to induce sickling of erythrocytes and simulate the vaso-occlusions
of sickle cell disease.214 Occlusions decreased the flow of sample despite a constant driving
pressure, and this readout was used to identify and stratify patients with sickle cell disease.
A related device examined occlusions due to platelet aggregation, a key pathological event
in heart attack and stroke,215 and innovative hematocrit measurements were based on
progressive packing of erythrocytes in serpentine channels (Figure 7b).205
Some clinical applications require recovery of intact, viable cells after an assay or post-
treatment. Storage of viable oocytes benefitted from the precise fluid handling for controlled
delivery of cryo-protective agents (CPAs).216 The device controlled loading of CPAs with
user-defined concentration profiles in as little as 15 min, which reduced both the osmotic
damage and the toxicity of the CPAs to the oocytes. Another device monitored glucose
metabolism by delivering a fluorogenic substrate to up to 10 live mouse embryos.217 The
reaction was monitored without using DNA-damaging UV excitation or electrically-driven
flow, and the resulting data could be used to select for human embryos most likely to
implant successfully. Another group purified hematopoietic stem cells from harvested bone
marrow for regenerative medicine using a PDMS filter that achieved greater than 90%
enrichment and post-separation viability.218
Microorganisms: A number of clinical assays detect medically-relevant microorganisms,
and recent microfluidic platforms have improved on larger-scale detection approaches.
When utilized on-chip, these methods have detected viruses, such as respiratory
viruses,219,220 hepatitis B and C,134,221 and HIV,221 as well as bacteria, most notably M.
tuberculosis (Figure 8a),136 methicillin-resistant Staphylococcus aureus (MRSA),222 and
Treponema pallidum, which causes syphilis.223 Because of the specificity of genetic and
protein biomolecules, PCR and immunoassays represent the mainstay of microbiological
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detection for microfluidic platforms. For example, SlipChips enabled multivolume digital
RT-PCR to quantify viral loads of HIV and hepatitis C virus.221 Immune- and PCR-based
approaches were also combined to collect and detect, respectively, H1N1 influenza viruses
from a throat swab.219 Another approach used nanostructured microelectrodes coated with
sequence-specific peptide nucleic acid probes to detect genetic material from pathogens
electrocatalytically.222 To inform treatment decisions, a recent study evaluated antibiotic
sensitivity in a bacterial population in 100 min using a “microviscometer.”224 Monitoring
the rotational period of magnetic beads in a bacterial suspension was used to quantify
bacterial proliferation in the presence of various antibiotic concentrations. Ongoing efforts
are needed to increase integration to minimize sample preparation and the use of expensive
lab equipment, in order to translate these devices to the bedside, the clinic, or resource-poor
areas.
Point-of-Care—Devices that achieve short sample-to-answer processing times, require
little outside equipment, and provide an easily-interpreted readout are especially suitable as
point-of-care (POC) platforms. While these features are difficult to achieve, many groups
have advanced the field by integrating multiple steps onto a single chip. For example, a
tunable acoustic device used multiple frequencies to complete an entire immunoassay using
a single transducer and a lens-free detection system.225 Similarly, a “lab-on-a-disc”
integrated sample loading, mixing, and incubation by spinning the disc at different speeds,
followed by multiplexed analysis of three protein biomarkers (Figure 8b).226
POC devices that operate with minimal external equipment and provide clear readout are
especially useful in resource-poor regions, such as rural areas or the developing world. For
example, the “Squeeze-chip,” which generated precise flow patterns using only finger
pumping by the operator, removed the need for outside pumps.227 Devices that provided
clear readout without expert interpretation of results or complex analytical equipment
included a device in which antibody analytes induced polymerization of a blocking material
in indicator channels (Figure 7c).228 Similarly, an RT-PCR-based device indicated influenza
virus detection within 1 min of operation using fluorophore-labeled primers that could be
immobilized on an absorbent pad and visualized.229 Paper microfluidic devices are
especially useful because they store well and are low cost, and four examples paired these
advantages with simple, colorimetric readouts appropriate for use by technicians with
limited training.203,208,209,230 An excellent POC example, a microfluidic ELISA called the
“mChip,” was developed through collaboration of chemists, engineers, clinicians, and public
health workers (Figure 8c).223 mChips were made inexpensively ($0.10/device) and rapidly
(40 s) on a large scale, featured discrete reagent delivery using manual syringe pumping, and
achieved quantitative detection of HIV or syphilis bacterial infection in approximately 5
min. Interpretation was performed qualitatively or quantitatively using a cell-phone-like
device to measure optical density. Most importantly, the device was validated with samples
from patients during extensive field-testing and optimization in Rwanda.
Microfluidic devices intended for clinical applications have much to gain from
collaborations between physicians, clinical chemists and engineers for two reasons. First,
clinicians have ready access to patient samples, the analysis of which is the true gold
standard for a new clinical device. We chose many of the devices in this section because
they were validated using patient samples from both diseased and normal subjects. Second,
the experiences of medical professionals help highlight critical gaps in medical diagnostic
technology. For example, several devices already exist that measure glucose in human
serum with sufficient analytical power, but a new platform that lowers detection limits for
cardiac biomarkers would improve early detection of heart attacks. Establishing a dialogue
with clinicians makes certain that new devices meet a medical need.
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Speed and Portability—The same advances in speed and portability that benefit point-
of-care analyses also make non-clinical analytical technologies field-ready. In particular, the
development of portable detection systems and sample preparation methods facilitates
successful transition of μTAS from the lab to the field.
Integration: Speed and portability benefit from fully integrated systems, which often
contain complex electrical, mechanical, and optical components. Advanced integration
simplifies devices, making them more user-friendly, and often increases information
content. Recent advances in this area have included a water-activated, self-heating cartridge
for a nucleic acid amplification chip231 and a microfabricated thermal modulator for sample
transfer in 2D gas chromatography.232 Advances in self-powered devices included
integrated batteries capable of powering electrochromic detection,233 an on-chip fuel cell
that supplied electrical and pumping power (Figure 9a),234 and galvanic cells that powered
an LED when sample was added to a paper-based device.235 Another autonomous system
was a lab-on-a-robot, which contained a temperature-controlled microfluidic device
integrated with capillary electrophoresis that could be operated by long-range remote control
on an all-terrain vehicle.236 In other cases, integrated components increased the information
content produced by lab-on-a-chip devices. For example, a recent device for environmental
samples integrated a 3D mixer, an LED array, photodetector, and accompanying electronics
for colorimetric detection at seven wavelengths, allowing determination of phenols,
chromium (VI), and nitrite.237 While integrated sample pre-treatment is still needed to
prepare this device for field applications, the automation and robustness of the device make
it appropriate for environmental automatic alert stations.
Sample Preparation: Streamlining sample preparation is a key challenge in any analysis,
and field applications must accommodate diverse samples and matrices, including gases,
aerosols, heterogeneous solids, such as foodstuffs and soil, and biological cells. Integrated
sample preparation is often necessary for field-ready devices and has the additional
advantage of increasing analysis speed. One notable example of on-chip sample clean-up
was a microfluidic gradient elution moving boundary electrophoretic (GEMBE) device
capable of removing dirt from aqueous environmental samples.238 Recent devices for
microfluidic liquid-liquid extractions included a centrifugal chip with automated pneumatic
recirculation239 and a honey-comb patterned silicon microchannel capable of extracting
sulfides from both water and oil.240 For gas phase or airborne analytes, devices may transfer
the sample to an aqueous phase. For example, a microfluidic aerosol-to-hydrosol sampler
converted analytes from a gas to a liquid phase and was coupled to silicon nanowire sensors
for near real-time detection of airborne viruses.241 Another device utilized a 3D gas/liquid
laminar flow to extract and concentrate ammonia from air and operated continuously for
three weeks in a cleanroom at nearly 100% extraction efficiency.242 Another on-chip system
distilled gaseous sulfur dioxide (SO2) from wine; this device will allow wine producers to
measure SO2on site, rather than shipping samples to laboratories (Figure 9b).243 Other
devices accepted real-world samples with minimal processing, such as a device to measure
methanol content in red wine with an integrated microreactor and detection channels
designed to fit into a standard UV spectrophotometer.244
Environmental Safety and Public Health—Low cost, portable, and high-speed
microfluidic systems contribute to many environmental safety and public health
applications. Recent advances are providing rapid, on-demand testing for hazardous
contaminates in our water and air.
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Water safety: Water analysis has a long history of field-compatible methods, and
microfluidic devices are extending and adding to existing techniques for on-site water
testing. Water analysis is conducted for public safety reasons as well as to monitor changes
in naturally occurring species for environmental studies. Many groups have made
improvements in the cost and portability of devices that measure chemical pollutants in
water, especially for applications in countries with increasing industrialization. Multiplexed
assays based on paper microfluidics230 and microchip electrophoresis245 have been
demonstrated for rapid, portable heavy metal detection in water samples. However, neither
of these devices consistently yielded limits of detection below the World Health
Organization guidelines for metals of interest.246 In order to be useful for public safety
testing, the detection limits of these devices must be decreased. A recent device for nitrate
and nitrite testing exemplified the characteristics required for practical application of
microfluidic water analysis devices; this system had an environmentally-relevant dynamic
range, measured samples every 10 min, and was continuously deployed in a river for 26
days.247 These benchmarks of sensitive, robust operation should be goals for all researchers
developing field-ready systems.
Detecting microorganisms in water for environmental and public safety applications is
similar to chemical detection but often includes the additional challenge of species
specificity. Devices to identify pathogenic, waterborne bacteria included an immunoassay
with electrochemical impedance spectroscopy detection,248 a multiplexed nanoparticle-
based DNA barcode immunoassay with electrophoresis,249 a compact, modular device for
PCR and array-based detection,250 and a fluorescence in situ hybridization (FISH) assay
coupled to a microfluidic flow cytometer.251 This latter detection strategy was used to
identify bacteria at a contaminated environmental site in Hanford, WA. Both non-pathogenic
and pathogenic algae were also targets for microfluidic detection. Measuring changes in the
type of algae species can be an effective way to monitor the environmental impact of climate
change. For this reason, identification of five algae species was conducted using a machine-
learning algorithm to classify the intensity distribution of laser light from a microfabricated
waveguide.252 In addition, several devices were designed to assay algal biochemicals for
public safety reasons. A microfluidic immunoassay measured three algal toxins in 2/3 the
time of conventional ELISA and with 1000x lower reagent volumes (Figure 9c).76 Another
device used a microchannel integrated with an LED, filter set, and photodiode to measure
the fluorescence of chlorophyll in algae as an indicator for algal stress in the presence of
chemical pollutants.253
Security, Defense, and Public Safety: Portable, automated microfluidic systems have
obvious advantages for security, defense, and workplace safety applications. A recent device
successfully detected biological and chemical warfare agents, including anthrax, ricin, and
explosives. The eight-channel device used a commercial detector with disposable cartridges
containing antibody-coated waveguides to monitor binding of anthrax spores, F. tularensis
cells, Vaccinia virus, and ricin toxin.254 Antibody-coated field effect transistors (FETs)
provided another sensitive non-optical detection technique for lab-on-a-chip applications.
On-chip FET sensors have been integrated in microchannels241 and a digital device;255 both
platforms were applied to virus detection on a seconds to minutes timescale. Hazardous
aerosols, particulates, and gases are additional public health and workplace safety issues that
can be addressed by microfluidics. Two recent devices assayed particulate matter for
oxidative activity256 and metal content.257 The first apparatus included a particle-to-liquid
sampling system and used a colorimetric reaction with oxidized dithiothreitol to determine
oxidative activity.256 The second device dissolved metal particulates, such as those from
machining or transportation services, and detected μg-levels using filter paper-based fluidics
to decrease turn-around time from sampling to measurement.257 Other instruments with
workplace safety applications detected potentially hazardous gases using
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chemiresistors.258,259 In one example, chemiresistive sensing was paired with microfluidic
GC separation for in-home screening for trichloroethylene (TCE) 259 a toxic gas that can
seep into homes from groundwater. The portable system detected TCE levels below the
Environmental Protection Agency regional screening limit and identified sources of
contamination in real-world environments.
In most public safety applications, rapid results are critical; however, many binding-based
detection methods integrate signal over time, which can limit analysis speed. For example,
several of the devices discussed here require 10-60 min to obtain signal-to-noise ratios
sufficient for reliable detection.76,248,249,254 While this time frame is acceptable for some
applications, in emergency situations dangerous chemicals and infectious pathogens must be
detected as rapidly as possible. Consequently, the signal-to-noise ratio as a function of time
must be improved for many of these systems to establish their utility in real-life situations.
Challenging Environments—Some field environments present unique technical
challenges, especially for analyses conducted at sea or in outer space. Measuring chemical
or biological species in the ocean requires robust, sensitive, and high-throughput devices to
achieve high spatial resolution on moving vehicles. A submersible microfluidic platform
performed displacement-based immunoaffinity assays for explosive compounds from bombs
planted by terrorists or left by former military operations (Figure 10a).260 This device
detected trinitrotoluene (TNT) 60 times faster and with two orders of magnitude more
sensitivity than conventional techniques. Other devices targeted biologically-relevant
analytes. For example, a device for the colorimetric detection of ocean nutrients utilized a
multiplexed stop-flow system to perform measurements with high spatial resolution,
allowing it to be deployed on moving vehicles, such as buoys or ocean gliders.261 Another
device for an underwater bioluminescence assay of microbial activity was successfully
operated at a shallow hot spring in Okinawa (Figure 10b).262 The microfluidic device,
electronics and photomultiplier tube were contained in a pressurized vessel and waste was
collected rather than dispensed into the environment. In another system, acoustic radiation
was used to collect and trap microorganisms in a microfluidic device at a depth of 1200
meters.263 These submersible microfluidic devices have displayed impressive robustness
and accuracy in the ocean – one of the most analytically challenging environments on the
planet – where they are surrounded by high salt concentrations, high pressures, fluctuating
temperatures, and abundant biological activity.
Another challenging environment for analysis is outer space, where devices must be
compact and completely autonomous for months on end. Highly integrated and automated
instrumentation enables the use of microfluidic devices on unmanned space flights. A recent
system executed completely automated fluorescent-labeling, electrophoretic separation, and
detection of amino acids on a single chip for the first time for eventual application in
astrobiology studies on Mars and elsewhere.264 Microfluidic devices have also been
developed to study the effects of gravitational fields265 and ionizing radiation266 on
biological processes. For example, microfluidic patch clamping experiments during
parabolic flight showed varying sodium channel activity under hyper- and microgravity
(Figure 10c).265 In addition to affecting biological specimens, microgravity changes fluidic
behavior in μTAS. In microgravity, cells do not settle and convective fluid flow is minimal.
These considerations affected a study of Bacillus subtilis germination conducted in low
earth orbit.266 A deeper understanding of the effects of microgravity on fluidic operations
coupled with a further increase in robustness will make μTAS valuable research tools for
extraterrestrial exploration.
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The wide range of laboratory, clinical, and field applications discussed here highlights the
versatility of μTAS. While miniaturized analysis is not well-suited to every application,
exceptional device performance can be achieved by thoughtfully matching the strengths of
microscale systems to specific applications. New research areas (such as the novel physical
and biological applications noted here) demonstrate that microfluidics has much to
contribute beyond the well-established area of microscale separations.
In the research laboratory, microfluidic systems continue to reduce reagent consumption,
decrease analysis time, and automate analyses in traditional applications like biochemical
assays. These benefits also contribute to on-chip syntheses of molecular and supramolecular
entities. Although synthetic applications are not directly relevant to analysis, the
development of microreactors on-chip represents a unique opportunity for microfluidics
researchers to contribute to interdisciplinary efforts that may have downstream analytical
relevance, for example, contrast agents for clinical imaging. The characteristic attributes of
microdevices have also enhanced systems for cell culture, manipulation, and analysis. As
biological applications of microfluidics mature, devices provide more sophisticated cell
culture platforms and probe biological systems across a broad range of complexities from
cells to tissues to organisms.
A true lab-on-a-chip should not require an external, macroscale laboratory to support its
operation. Consequently, μTAS designed for clinical and field applications must be robust
and portable. To convince clinicians, field biologists, environmental scientists, and public
safety officers to adopt μTAS in their work, researchers must analyze real samples in real-
world scenarios and non-laboratory settings. To accomplish this, researchers must often
address challenges beyond chemical analysis and find engineering solutions for portable
power sources, intuitive readout, and remote operation. As interdisciplinary teams advance
microfluidic technology, μTAS will contribute to new analytical methods in the research lab
and beyond.
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ATR-FTIR attenuated total reflection Fourier-transform infrared
CTC circulating tumor cell
CPA cryo-protective agent
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ELISA enzyme-linked immunosorbent assay
EGF epidermal growth factor
EpCAM epithelial cell adhesion molecule
ECM extracellular matrix
FET field effect transistor
FISH fluorescence in situ hybridization
GEMBE gradient elution moving boundary electrophoresis
HUVEC human umbilical vein endothelial cell
MRI magnetic resonance imaging
MRSA methicillin-resistant Staphylococcus aureus
μTAS micro total analysis systems
POC point-of-care
PDMS polydimethylsiloxane
PCR polymerase chain reaction
PMMA polymethylmethacrylate
PTFE polytetrafluoroethylene
PET positron emission topography
qPCR quantitative polymerase chain reaction
RT-PCR reverse-transcriptase polymerase chain reaction
REEAD rolling-circle-enhanced enzyme activity detection
SPR surface plasmon resonance
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Recent fundamental advances included (a) new microfabrication methods, (b) integration
with acoustics, and (c) integration with biomimetic mechanical systems. (a) An illustration
of a self-assembling microfluidic device with PDMS channels integrated with a
differentially crosslinked SU-8 film attached to a silicon substrate. From ref 6. Reprinted
with permission from Nature Publishing Group. (b) Acoustic tweezers with orthogonal pairs
of chirped interdigital transducers for generating a standing surface acoustic wave field.
Reprinted with permission from ref 17. Copyright 2012 National Academy of Sciences. (c)
A soft robot glowing in the dark using chemiluminescence. (Inset) The same robot
photographed in the light. From ref 29. Reprinted with permission from AAAS.
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Recent devices used microfluidics to dispense liquids accurately off-chip with applications
in (a, b) cell-based assays and (c) scanning electrochemical microscopy. (a) This valve-less,
single channel pipette sequentially dispensed capsaicin and calcium for signaling studies in
single cells. Reproduced from ref 45 with permission of The Royal Society of Chemistry.
(b) A multichannel dispenser applied reagents to low-volume cell cultures. Reprinted from
ref 46. Copyright 2012 American Chemical Society. (c) A push-pull probe provided a
continuously renewed droplet of redox mediators for scanning electrochemical microscopy.
Reprinted from ref 47. Copyright 2011 American Chemical Society.
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On-chip synthesis. Microfluidic systems allowed for (a) continuous protein production, (b)
bicompartmental synthesis, (c) combinatorial synthesis, (d) mimicking of plant
photosynthesis and (e) synthesis of 3D solids. (a) Flow-based continuous cell-free protein
synthesis was performed in 40-μm diameter, 15-μm tall reaction vessels that contained
DNA templates and translation components. Reactants were delivered via flow, and
synthesized proteins were released through the container pores. From ref 90. Reproduced
with permission of The Royal Society of Chemistry. (b) Bicompartmental droplets allowed
analyte transport into an ionic liquid droplet to produce a fluorescent product that could be
decoupled from the combined droplets. From ref 93. Copyright 2012 John Wiley & Sons,
Inc. (c) A microfluidic device for combinatorial synthesis by droplet fusion utilized multiple
droplet injection regions and electrocoalescence-based droplet fusion. From ref 94.
Reproduced with permission of The Royal Society of Chemistry. (d) A microfluidic mimic
of natural photosynthesis incorporated CdSe quantum dots for light-dependent reaction
regions separate from light-independent reaction regions. From ref 95. Reproduced with
permission of The Royal Society of Chemistry. (e) A microfluidic device utilized two-
photon continuous flow lithography to produce 3D structures. From ref 104. Copyright 2012
John Wiley & Sons, Inc.
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Digitization advances included new means of droplet (a) generation and (b, c, d)
manipulation as well as (e) high-density digital PCR. (a) A dual-coaxial microfluidic device
produced gas/liquid/liquid double emulsions with a high degree of emulsion/droplet control.
From ref 115. Reproduced with permission of The Royal Society of Chemistry. (b) A grid of
electrodes allowed reagent actuation to the site of a dried blood spot for the quantification of
amino acids in blood via in-line mass spectrometry. From ref 116. Reproduced with
permission of The Royal Society of Chemistry. (c) Utilizing a silane-patterned open-surface
microfluidics device, droplets containing an insoluble surfactant (green) were self-propelled
along a sub-phase liquid (blue). From ref 122. Reproduced with permission of The Royal
Society of Chemistry. (d) Electrowetting forces laterally spread droplets. Upon removal of
electrowetting forces, the droplets converted stored energy to kinetic energy, causing them
to “jump” off the surface. Reprinted with permission from Lee, S., Lee, S. & Kang, K.
Droplet jumping by electrowetting and its application to the three-dimensional digital
microfluidics. Appl. Phys. Lett.100, 081604. Copyright 2012, American Institute of Physics
(ref 123). (e) High-density digitization of PCR samples into microscale compartments. This
“megapixel” digital PCR device had reaction vessel densities exceeding 440,000 cm−2 and a
dynamic range of 107. Reproduced from ref 127 with permission of the Nature Publishing
Group.
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Control of the cellular microenvironment. μTAS technology enabled new studies in a
variety of biological systems. (a) Selective release and tracking of newly-budded yeast
daughter cells across multiple generations controlled by microfluidic flow. Reprinted with
permission from ref 147. Copyright 2012 National Academy of Sciences. (b) A microfluidic
maze established tunable EGF gradients on the cellular level to study epithelial cell
migration. From ref 153. Reproduced with permission of the Royal Society of Chemistry.
(c) Chemokine-induced adenoid cystic carcinoma intravasation through a mock endothelial
cell monolayer in microfluidic-based device. Scale bar, 200 μm. From ref 159. Adapted by
permission from the Royal Society of Chemistry.
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Organs and organisms-on-chip. Microfluidics allowed controlled studies of (a,b) cell-cell
interactions and (c) whole organisms. (a) Time-lapse images of a red blood cells flowing
through a capillary network developed from endothelial cells cultured in a microfluidic
channel. From ref 165. Reproduced with permission of The Royal Society of Chemistry. (b)
Sprouting of mCherry-expressing endothelial cells (arrowheads) from a central lumen was
demonstrated within a co-culture of 10T1/2 cells expressing enhanced green fluorescent
protein. Scale bar, 200 μm. Adapted by permission from Macmillan Publishers Ltd: Nature
Materials, ref 170, copyright 2012. (c) A microfluidic device for examining behavioral
responses of C. elegans to chemical changes. Scale bars, 500 μm. Adapted by permission
from Macmillan Publishers Ltd: Nature Methods, ref 180, copyright 2012.
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Clinically-relevant microfluidic devices for (a, b) whole cell analyses and (c) easy readout.
(a) Hydrodynamic pressure applied to cells from the chest wall of patients allowed
identification of malignancy by monitoring the mechanical deformability of single cells at a
rate of 2000 cells/s. Reproduced from ref 213. Copyright 2012, National Academy of
Sciences, USA. (b) A microfluidic device for ELISA-based measurements from whole
blood. The device separated plasma from red blood cells for subsequent immunosensing.
The serpentine channels also allowed for quantification of serum hematocrit, based on the
length of the packed red blood cells. Reproduced from ref 205 with permission of The Royal
Society of Chemistry. (c) Antigen-responsive microfluidic valves for easily interpreted
results. Introduction of an antigen into an antibody-packed column led to polymerization and
blockage of subsequent flow, which was used to visualize test results. Reproduced from ref
228 with permission of The Royal Society of Chemistry.
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(a) Nucleic acid amplification and (b, c) immunosensing-based microfluidic devices for
clinical use. (a) Integrated platform for detecting drug resistance genotypes in
Mycobacterium tuberculosis. The system incorporated a cell lysis region, PCR amplification
and LDR-based detection with integrated optics. Reproduced from ref 136 with permission
of The Royal Society of Chemistry. (b) Immunosensing ELISA performed on a lab-on-a-
disc to measure levels of human C-reactive protein, cardiac troponin I, or N-terminal
prohormone of brain natriuretic peptide. Reproduced from ref 226. Copyright 2012
American Chemical Society. (c) Immunosensing device for detecting infectious
microorganisms (HIV and Treponema pallidum, which causes syphilis). This device was
field-tested in resource-poor areas of Rwanda. Reproduced from ref 223. Adapted by
permission from Macmillan Publishers Ltd: Nature Medicine, copyright 2012.
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These highly portable devices are suitable for use in the field. (a) A self-powered
microfluidic device that included a methanol fuel cell. Reproduced from ref 234 with
permission of The Royal Society of Chemistry. (b) An on-chip distiller for measuring SO2
concentrations in wine at the production or bottling site. Reproduced from ref 243 with
permission of The Royal Society of Chemistry. (c) An integrated immunoassay device for
monitoring algal cyanotoxins in natural waters. Reproduced from ref 76 with permission of
The Royal Society of Chemistry.
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μTAS have been designed for deployment in highly challenging environments, including (a)
the ocean, (b) hot springs, and (c) outer space. (a) A submersible microfluidic device for
detecting explosive compounds in the ocean. Reprinted from ref 260. Copyright 2011
American Chemical Society. (b) A pressurized vessel containing a photomultiplier tube,
electronics, and a microfluidic device for measuring microbial activity in a shallow hot
spring. Reproduced from ref 262 with permission of The Royal Society of Chemistry. (c) A
microfluidic device for voltage clamp studies of oocytes during parabolic flight. Reproduced
from ref 265 with permission of The Royal Society of Chemistry.
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